The decision to postpone the list change is due to the prioritization of the acquisition of seven product licenses in Denmark during the spring and winter, which was announced on March 15, 2021. Through that prioritization, the company needed to move resources from the listing process to the acquisition. This in combination with sick leave among key personnel has led to delays in reviewing and updating the routines required for listing on Nasdaq Stockholm's main list. The postponement of the list change does not mean a strategic change for EQL Pharma, but only that the list change takes place after the summer instead of before.